Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con Argument
The management of patients with symptomatic chronic obstructive pulmonary disease (COPD) has become more clear in the past several years. New medications have been developed and their efficacy has been evaluated using important outcomes in addition to forced expiratory volume in 1 s (FEV1), suc...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2004-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2004/284010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399807269928960 |
|---|---|
| author | Jeremy Road |
| author_facet | Jeremy Road |
| author_sort | Jeremy Road |
| collection | DOAJ |
| description | The management of patients with symptomatic chronic obstructive pulmonary disease (COPD) has become more clear in the past several years. New medications have been developed and their efficacy has been evaluated using important outcomes in addition to forced expiratory volume in 1 s (FEV1), such as health-related quality of life (HRQL), frequency of exacerbations and dyspnea scores. I will review five welldesigned, randomized, controlled trials that have advanced our knowledge about the use of inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs) and their combination. |
| format | Article |
| id | doaj-art-9ce9470b36e24632b7ad41b22778a143 |
| institution | Kabale University |
| issn | 1198-2241 |
| language | English |
| publishDate | 2004-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-9ce9470b36e24632b7ad41b22778a1432025-08-20T03:38:15ZengWileyCanadian Respiratory Journal1198-22412004-01-0111322422610.1155/2004/284010Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con ArgumentJeremy RoadThe management of patients with symptomatic chronic obstructive pulmonary disease (COPD) has become more clear in the past several years. New medications have been developed and their efficacy has been evaluated using important outcomes in addition to forced expiratory volume in 1 s (FEV1), such as health-related quality of life (HRQL), frequency of exacerbations and dyspnea scores. I will review five welldesigned, randomized, controlled trials that have advanced our knowledge about the use of inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs) and their combination.http://dx.doi.org/10.1155/2004/284010 |
| spellingShingle | Jeremy Road Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con Argument Canadian Respiratory Journal |
| title | Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con Argument |
| title_full | Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con Argument |
| title_fullStr | Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con Argument |
| title_full_unstemmed | Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con Argument |
| title_short | Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Con Argument |
| title_sort | combination of icss and labas should be used in the management of patients with copd the con argument |
| url | http://dx.doi.org/10.1155/2004/284010 |
| work_keys_str_mv | AT jeremyroad combinationoficssandlabasshouldbeusedinthemanagementofpatientswithcopdtheconargument |